Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
Zacks
More News
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
Zacks
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
Zacks
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
Zacks
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +5.26% and +0.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. Second Quarter 2026 Financial Highlights Total revenue of $22.8...
Business Wire
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx (CVRX) delivered earnings and revenue surprises of -1.92% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Companys Premarket Approval Panel Track Supplement seeking to expand the labeled indication for...
Business Wire
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
Zacks
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant(TM)
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant...
Yahoo! Finance: News

Advertisement|Remove ads.